Related Experiment Video
Updated: Jul 14, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
BACE1 expression and activity: relevance in Alzheimer's disease
Daniele Zacchetti1, Evelina Chieregatti, Barbara Bettegazzi
1Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milano, Italy. zacchetti.daniele@hsr.it
Neuro-Degenerative Diseases
|June 29, 2007
Summary
The discovery of Beta-secretase 1 (BACE1) is crucial for Alzheimer's disease research. Studies now explore BACE1 activity and expression changes to understand disease mechanisms and develop new therapeutic strategies.
Area of Science:
- Neuroscience
- Biochemistry
- Pharmacology
Background:
- Alzheimer's disease (AD) pathogenesis involves amyloid-beta (Aβ) peptide accumulation.
- Beta-secretase 1 (BACE1) initiates Aβ generation, making it a key therapeutic target.
- Understanding BACE1's role in AD progression is critical for developing effective treatments.
Purpose of the Study:
- To review recent findings on BACE1 expression and activity in Alzheimer's disease.
- To highlight new pathogenetic paradigms emerging from BACE1 research.
- To identify contrasting viewpoints and promising future directions in BACE1-targeted AD research.
Main Methods:
- Literature review of experimental models and human studies on BACE1.
- Analysis of BACE1 expression and activity data.
- Synthesis of current research to identify trends and controversies.
Main Results:
- Significant advancements have been made in understanding BACE1's role in AD.
- New pathogenetic models are emerging based on BACE1 research.
- Contrasting data and areas requiring further investigation have been identified.
Conclusions:
- BACE1 remains a central focus in Alzheimer's disease research.
- Further research is needed to confirm emerging findings and resolve conflicting data.
- Promising therapeutic perspectives are emerging from the study of BACE1 activity and expression.
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:58Cell Specific Gene Expression
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...